161 related articles for article (PubMed ID: 30276959)
1. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: The impact of pre-existing diabetes mellitus.
Li Z; Gao Z; Xiang J; Zhou J; Yan S; Hu Z
Liver Int; 2019 Feb; 39(2):361-370. PubMed ID: 30276959
[TBL] [Abstract][Full Text] [Related]
2. Intention-to-treat analysis of liver transplantation for hepatocellular carcinoma: living versus deceased donor transplantation.
Bhangui P; Vibert E; Majno P; Salloum C; Andreani P; Zocrato J; Ichai P; Saliba F; Adam R; Castaing D; Azoulay D
Hepatology; 2011 May; 53(5):1570-9. PubMed ID: 21520172
[TBL] [Abstract][Full Text] [Related]
3. Living or Brain-dead Donor Liver Transplantation for Hepatocellular Carcinoma: A Multicenter, Western, Intent-to-treat Cohort Study.
Azoulay D; Audureau E; Bhangui P; Belghiti J; Boillot O; Andreani P; Castaing D; Cherqui D; Irtan S; Calmus Y; Chazouillères O; Soubrane O; Luciani A; Feray C
Ann Surg; 2017 Dec; 266(6):1035-1044. PubMed ID: 27617853
[TBL] [Abstract][Full Text] [Related]
4. Resection vs Transplant Listing for Hepatocellular Carcinoma: An Intention-to-Treat Analysis.
Meyerovich G; Goykhman Y; Nakache R; Nachmany I; Lahat G; Shibolet O; Menachem Y; Katchman H; Wolf I; Geva R; Klausner JM; Lubezky N
Transplant Proc; 2019; 51(6):1867-1873. PubMed ID: 31399171
[TBL] [Abstract][Full Text] [Related]
5. Diabetes mellitus may affect the long-term survival of hepatitis B virus-related hepatocellular carcinoma patients after liver transplantation.
Zhang Q; Deng YL; Liu C; Huang LH; Shang L; Chen XG; Wang LT; Du JZ; Wang Y; Wang PX; Zhang H; Shen ZY
World J Gastroenterol; 2016 Nov; 22(43):9571-9585. PubMed ID: 27920478
[TBL] [Abstract][Full Text] [Related]
6. Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs. deceased donation.
Goldaracena N; Gorgen A; Doyle A; Hansen BE; Tomiyama K; Zhang W; Ghanekar A; Lilly L; Cattral M; Galvin Z; Selzner M; Bhat M; Selzner N; McGilvray I; Greig PD; Grant DR; Sapisochin G
J Hepatol; 2019 Apr; 70(4):666-673. PubMed ID: 30630009
[TBL] [Abstract][Full Text] [Related]
7. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: A 10-year intention-to-treat analysis.
Lee MW; Raman SS; Asvadi NH; Siripongsakun S; Hicks RM; Chen J; Worakitsitisatorn A; McWilliams J; Tong MJ; Finn RS; Agopian VG; Busuttil RW; Lu DSK
Hepatology; 2017 Jun; 65(6):1979-1990. PubMed ID: 28170115
[TBL] [Abstract][Full Text] [Related]
8. Survival benefit of transplantation for recurrence of hepatocellular carcinoma after liver resection.
Tuci F; Vitale A; D'Amico F; Gringeri E; Neri D; Zanus G; Bassi D; Polacco M; Boetto R; Lodo E; Germani G; Burra P; Angeli P; Cillo U
Transplant Proc; 2014 Sep; 46(7):2287-9. PubMed ID: 25242770
[TBL] [Abstract][Full Text] [Related]
9. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Intention-to-Treat Benefit of Living Donation in Patients With Hepatocellular Carcinoma Awaiting a Liver Transplant.
Lai Q; Sapisochin G; Gorgen A; Vitale A; Halazun KJ; Iesari S; Schaefer B; Bhangui P; Mennini G; Wong TCL; Uemoto S; Lin CC; Mittler J; Ikegami T; Yang Z; Frigo AC; Zheng SS; Soejima Y; Hoppe-Lotichius M; Chen CL; Kaido T; Lo CM; Rossi M; Soin AS; Finkenstedt A; Emond JC; Cillo U; Lerut JP
JAMA Surg; 2021 Sep; 156(9):e213112. PubMed ID: 34259797
[TBL] [Abstract][Full Text] [Related]
11. Limited tumour progression beyond Milan criteria while on the waiting list does not result in unacceptable impairment of survival.
Ferrer-Fàbrega J; Sampson-Dávila J; Forner A; Sapena V; Díaz A; Vilana R; Navasa M; Fondevila C; Miquel R; Ayuso C; García-Valdecasas JC; Bruix J; Reig M; Fuster J
J Hepatol; 2021 Nov; 75(5):1154-1163. PubMed ID: 34171433
[TBL] [Abstract][Full Text] [Related]
12. Excellent Outcomes of Liver Transplantation Following Down-Staging of Hepatocellular Carcinoma to Within Milan Criteria: A Multicenter Study.
Mehta N; Guy J; Frenette CT; Dodge JL; Osorio RW; Minteer WB; Roberts JP; Yao FY
Clin Gastroenterol Hepatol; 2018 Jun; 16(6):955-964. PubMed ID: 29175528
[TBL] [Abstract][Full Text] [Related]
13. Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.
Huang AC; Mehta N; Dodge JL; Yao FY; Terrault NA
Hepatology; 2018 Aug; 68(2):449-461. PubMed ID: 29476694
[TBL] [Abstract][Full Text] [Related]
14. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
15. Liver transplantation for hepatocellular carcinoma beyond the Milan criteria.
Xu X; Lu D; Ling Q; Wei X; Wu J; Zhou L; Yan S; Wu L; Geng L; Ke Q; Gao F; Tu Z; Wang W; Zhang M; Shen Y; Xie H; Jiang W; Wang H; Zheng S
Gut; 2016 Jun; 65(6):1035-41. PubMed ID: 25804634
[TBL] [Abstract][Full Text] [Related]
16. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis.
Mazzaferro V; Llovet JM; Miceli R; Bhoori S; Schiavo M; Mariani L; Camerini T; Roayaie S; Schwartz ME; Grazi GL; Adam R; Neuhaus P; Salizzoni M; Bruix J; Forner A; De Carlis L; Cillo U; Burroughs AK; Troisi R; Rossi M; Gerunda GE; Lerut J; Belghiti J; Boin I; Gugenheim J; Rochling F; Van Hoek B; Majno P;
Lancet Oncol; 2009 Jan; 10(1):35-43. PubMed ID: 19058754
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk factors of hepatocellular carcinoma after orthotopic liver transplantation.
Colhoun ED; Forsberg CG; Chavin KD; Baliga PK; Taber DJ
Surgery; 2017 Mar; 161(3):830-836. PubMed ID: 27771158
[TBL] [Abstract][Full Text] [Related]
18. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Survival Outcome Between Living Donor and Deceased Donor Liver Transplant for Hepatocellular Carcinoma: Intention-to-Treat and Propensity Score Matching Analyses.
Wong TCL; Ng KKC; Fung JYY; Chan AAC; Cheung TT; Chok KSH; Dai JWC; Lo CM
Ann Surg Oncol; 2019 May; 26(5):1454-1462. PubMed ID: 30737669
[TBL] [Abstract][Full Text] [Related]
20. Predictive factors for extrahepatic recurrence of hepatocellular carcinoma following liver transplantation.
Andreou A; Bahra M; Schmelzle M; Öllinger R; Sucher R; Sauer IM; Guel-Klein S; Struecker B; Eurich D; Klein F; Pascher A; Pratschke J; Seehofer D
Clin Transplant; 2016 Jul; 30(7):819-27. PubMed ID: 27107252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
